Table 1.

Results of Questions 1–3 and comparison with the previous survey. In italics: p = 0.0001, otherwise p > 0.05.

Question 1		Current survey (n = 1322)	Previous survey (n = 1059)
Exposure to anti-TNF therapy (infliximab (Remicade), adalimumab (Humira), certolizumab (Cimzia), golimumab (Simponi)	Currently treated with anti-TNF	500 (58.9%) of CD patients (n = 849), 176 (37.2%) of UC patients (n = 473)	347 (52.9%) of CD patients (n = 657), 130 (32.3%) of UC patients (n = 402)
	Received anti-TNF in the past, therapy discontinued due to inefficacy	104 (8.2%)	73 6.9%
	Received anti-TNF in the past, therapy discontinued due to side effects	108 (7.9%)	74 7.0%
Question 2		Current survey (n = 1221)	Previous survey
Have you been previously or are you currently being treated with an infliximab biosimilar (INFLECTRA, REMSIMA or FLIXABI)?	Yes	230 18.8%	n/a
Question 3		Current survey (n = 1355)	Previous survey (n = 1059)
Have you ever heard of biosimilars?	Yes	596 (44.0%)	383 (36.2%)